Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2012

01.07.2012 | Breast Oncology

Race and the Prognostic Influence of p53 in Women with Breast Cancer

verfasst von: Keith A. Dookeran, MBBS, FRCS(Ed), MD, MBA, James J. Dignam, PhD, Nathaniel Holloway, MD†, Karen Ferrer, MD, Marin Sekosan, MD, Worta McCaskill-Stevens, MD, Sarah Gehlert, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Prior study suggests that p53 status behaves as an independent marker of prognosis in African American (AA) women with breast cancer. We investigate whether the influence of p53 is unique to AAs or is present in other race/ethnic groups, and how this compares with known prognostic factors.

Methods

Cox regression models [hazard ratios (HRs), 95% confidence intervals (CIs)] were used to select and evaluate factors prognostic for all-cause mortality in 331 AA and 203 non-AA consecutively treated women.

Results

Statistically significant baseline prognostic factors were as follows. For AAs: stage [(III/I) HR 5.57; 95% CI 3.08–10.09], grade [(higher/low) HR 1.55; 95% CI 1.14–2.11], estrogen receptor (ER)/progesterone receptor (PR) status [(−/+) HR 2.01; 95% CI 1.38–2.93], triple negative (ER−, PR−, HER2−) subtype [(+/−) HR 1.95; 95% CI 1.33–2.85], and p53 status [(+/−) HR 1.69; 95% CI 1.10–2.58]. For non-AAs: stage [HR 11.93; 95% CI 2.80–50.84], grade [HR 1.61; 95% CI 0.96–2.71], and ER/PR status [HR 2.13; 95% CI 1.19–3.81]. There was a differential effect of race within p53 groups (P = 0.05) and in multivariate modeling p53-positive status remained an adverse prognostic factor in AAs only [HR 1.82; 95% CI 1.04–3.17]. Compared to non-AAs, 5-year unadjusted survival was worse for AAs overall (73.4% vs. 63.6%; P = 0.032), and also for AAs with p53-positive status (80.3% vs. 54.2%; P = 0.016), but not for AAs with p53-negative disease (68.4% vs. 67.9%; P = 0.81).

Conclusions

Among women with breast cancer of different race/ethnicity, an adverse prognostic effect as a result of p53 positivity was only observed in AA women.
Literatur
1.
Zurück zum Zitat Dookeran KA, Dignam JJ, Ferrer K, et al. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010;17:1398–405.PubMedCrossRef Dookeran KA, Dignam JJ, Ferrer K, et al. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010;17:1398–405.PubMedCrossRef
4.
Zurück zum Zitat Tehranifar P, Neugut AI, Phelan JC, et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev. 2009;18:2701.PubMed Tehranifar P, Neugut AI, Phelan JC, et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev. 2009;18:2701.PubMed
5.
Zurück zum Zitat Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.PubMedCrossRef Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.PubMedCrossRef
6.
Zurück zum Zitat Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003.
7.
Zurück zum Zitat Fleming ID, Cooper JS, Hensen DE, ed. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997. Fleming ID, Cooper JS, Hensen DE, ed. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
8.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, ed. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. Greene FL, Page DL, Fleming ID, ed. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
9.
Zurück zum Zitat Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer. 2004;100:2533–42.PubMedCrossRef Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer. 2004;100:2533–42.PubMedCrossRef
10.
Zurück zum Zitat Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef
11.
Zurück zum Zitat Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86:705–12.PubMedCrossRef Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86:705–12.PubMedCrossRef
12.
Zurück zum Zitat Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMed Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMed
13.
Zurück zum Zitat Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer; 2003. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer; 2003.
14.
Zurück zum Zitat Baker L, Quinlan PR, Patten N, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer. 2010;102:719–26.PubMedCrossRef Baker L, Quinlan PR, Patten N, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer. 2010;102:719–26.PubMedCrossRef
15.
Zurück zum Zitat Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004;101:1293–301.PubMedCrossRef Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004;101:1293–301.PubMedCrossRef
16.
Zurück zum Zitat Dookeran KA, Gao X, Ferrer K, et al. Evaluation of p53 immunoreactivity in African-American patients with breast cancer. Proceedings of the American Association for Cancer Research (94th Annual Meeting, July 11–14 2003, Washington, DC). 2003;44:295. Dookeran KA, Gao X, Ferrer K, et al. Evaluation of p53 immunoreactivity in African-American patients with breast cancer. Proceedings of the American Association for Cancer Research (94th Annual Meeting, July 11–14 2003, Washington, DC). 2003;44:295.
17.
Zurück zum Zitat Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients. Cancer. 2007;110:876–84.PubMedCrossRef Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients. Cancer. 2007;110:876–84.PubMedCrossRef
18.
Zurück zum Zitat Lai H, Lai S, Ma F, Meng L, Trapido E. Prevalence and spectrum of p53 mutations in white Hispanic and non-Hispanic women with breast cancer. Breast Cancer Res Treat. 2003;81:53–60.PubMedCrossRef Lai H, Lai S, Ma F, Meng L, Trapido E. Prevalence and spectrum of p53 mutations in white Hispanic and non-Hispanic women with breast cancer. Breast Cancer Res Treat. 2003;81:53–60.PubMedCrossRef
19.
Zurück zum Zitat Greenberg S, Rugo HS. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010;10:20–9.CrossRef Greenberg S, Rugo HS. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010;10:20–9.CrossRef
20.
Zurück zum Zitat Millar EKA, Graham PH, O’Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27:4701–8.PubMedCrossRef Millar EKA, Graham PH, O’Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27:4701–8.PubMedCrossRef
21.
Zurück zum Zitat Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1–10.PubMedCrossRef Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1–10.PubMedCrossRef
22.
Zurück zum Zitat Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.PubMedCrossRef Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.PubMedCrossRef
23.
Zurück zum Zitat Komenaka IK, Martinez ME, Pennington RE, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010;102:1178.PubMedCrossRef Komenaka IK, Martinez ME, Pennington RE, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010;102:1178.PubMedCrossRef
24.
Zurück zum Zitat Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat. 2010;121:281–92.PubMedCrossRef Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat. 2010;121:281–92.PubMedCrossRef
25.
Zurück zum Zitat DeNavas-Walt C, Proctor BD, Lee CH. Income, poverty, and health insurance coverage in the United States: 2005. In: U.S. Census Bureau. Current population reports. Washington: U.S. Government Printing Office; 2006. p. 60–231. DeNavas-Walt C, Proctor BD, Lee CH. Income, poverty, and health insurance coverage in the United States: 2005. In: U.S. Census Bureau. Current population reports. Washington: U.S. Government Printing Office; 2006. p. 60–231.
26.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef
27.
Zurück zum Zitat Dookeran K, Gao X, Wang Y, et al. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. AACR meeting abstracts, No. 2510. 14 Apr 2007. Dookeran K, Gao X, Wang Y, et al. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. AACR meeting abstracts, No. 2510. 14 Apr 2007.
28.
Zurück zum Zitat Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368.PubMedCrossRef Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368.PubMedCrossRef
29.
Zurück zum Zitat Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes. Cancer. 2010;116:2549–59.PubMed Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes. Cancer. 2010;116:2549–59.PubMed
30.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef
31.
Zurück zum Zitat Carstairs V, Morris R. Deprivation and health in Scotland. Aberdeen: Aberdeen University Press; 1991. Carstairs V, Morris R. Deprivation and health in Scotland. Aberdeen: Aberdeen University Press; 1991.
32.
Zurück zum Zitat Oliveira AM, Fletcher JA, Ross JS. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Pathol Patterns Rev. 2005;124:16–28.CrossRef Oliveira AM, Fletcher JA, Ross JS. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Pathol Patterns Rev. 2005;124:16–28.CrossRef
33.
Zurück zum Zitat Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–6.PubMedCrossRef Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–6.PubMedCrossRef
34.
Zurück zum Zitat Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L, Coplete J. Sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029–34.PubMedCrossRef Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L, Coplete J. Sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029–34.PubMedCrossRef
35.
Zurück zum Zitat Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8(6):R66.PubMedCrossRef Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8(6):R66.PubMedCrossRef
36.
Zurück zum Zitat Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6.PubMed Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6.PubMed
37.
Zurück zum Zitat Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845–55.PubMedCrossRef Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845–55.PubMedCrossRef
38.
Zurück zum Zitat Dookeran KA, Gao X, Wang Y, et al. p53 gene mutations in African-American women with breast cancer. Breast Cancer Res Treat. 2006;100(Suppl. 1):S145. Dookeran KA, Gao X, Wang Y, et al. p53 gene mutations in African-American women with breast cancer. Breast Cancer Res Treat. 2006;100(Suppl. 1):S145.
39.
Zurück zum Zitat Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994;343(8907):1195–7.PubMedCrossRef Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994;343(8907):1195–7.PubMedCrossRef
40.
Zurück zum Zitat Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55:1485–90.PubMed Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55:1485–90.PubMed
41.
Zurück zum Zitat Shiao YH, Chen VW, Wu XC, et al. Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo. 1996;10:169–73.PubMed Shiao YH, Chen VW, Wu XC, et al. Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo. 1996;10:169–73.PubMed
Metadaten
Titel
Race and the Prognostic Influence of p53 in Women with Breast Cancer
verfasst von
Keith A. Dookeran, MBBS, FRCS(Ed), MD, MBA
James J. Dignam, PhD
Nathaniel Holloway, MD†
Karen Ferrer, MD
Marin Sekosan, MD
Worta McCaskill-Stevens, MD
Sarah Gehlert, PhD
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1934-6

Weitere Artikel der Ausgabe 7/2012

Annals of Surgical Oncology 7/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.